secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-283649
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos reports Q3 net loss $8.9M; first objective response in TCR-T Library trial
--------------------------------------------------------------------------------

- Q3 2022 net loss $8.9M ($0.04/sh) vs $22.7M ($0.11/sh) in Q3 2021; revenue $2.9M from darinaparsin milestone.
- First patient with NSCLC achieved >50% tumor regression at 12 weeks with Sleeping Beauty TCR-T cells targeting KRAS G12D.
- TCR-T cell persistence observed: ~30% of blood T-cells at 24 weeks in patient 1; manageable safety, no ICANS.
- Manufacturing capacity doubled to produce two products simultaneously; IND amendment in 4Q22 to add two TCRs and switch to cryopreserved process (26 days vs 30).
- Cash $37.8M plus restricted cash $13.9M; operating cash burn $6.1M in Q3 2022, down 36% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/0001193125-22-283649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/d411392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-283649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer